Tissue heart valve mineralization: Review of calcification mechanisms and strategies for prevention

Journal of Applied Biomaterials and Biomechanics

Volumn 3, Issue 2, 2005, Pages 67-82

  Jorge Herrero, E ^a   Garcia Paez J M ^a   Del Castillo Olivares Ramos, J L ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Bioprostheses; Calcification; Cardiovascular; Crosslinking; Heart valves

Indexed keywords

ALKALINE PHOSPHATASE; AMINO ACID; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYANAMIDE; GLUTARALDEHYDE; MATRIX METALLOPROTEINASE; METAL ION; OLEIC ACID;

ANTICOAGULANT THERAPY; BIOPROSTHESIS; CALCIFICATION; CHEMICAL MODIFICATION; CROSS LINKING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART; HEART VALVE; HEART VALVE PROSTHESIS; MECHANICAL STRESS; MINERALIZATION; REVIEW; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

ANIMALIA; BOVINAE; SUIDAE;

EID: 28244484330     PISSN: 17226899     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Grunkemeier GL, Rahimtoola SH. Artificial heart valves. Annu Rev Med 1990; 41: 251-63.
2. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; 335: 407-16.
3. Schoen FJ, Levy RJ. Founder's Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res 1999; 47: 439-65.
4. Schoen FJ, Levy RJ. Heart valve bioprostheses: antimineralization. Eur J Cardiothorac Surg 1992; 6 (suppl 1): S91-3.
5. Schoen FJ. Cardiac valve prostheses: review of clinical status and contemporary biomaterials issues. J Biomed Mater Res 1987; 21 (suppl): S91-117.
6. Thubrikar MJ, Deck JD, Aouad J, Nolan SP. Role of mechanical stress in calcification of aortic bioprosthetic valves. J Thorac Cardiovasc Surg 1983; 86: 115-25.
7. Schoen FJ, Kujovich JL, Levy RJ, Sutton MS. Bioprosthetic valve failure. Cardiovasc Clin 1988; 18: 289-317.
8. Schoen FJ, Tsao JW, Levy RJ. Calcification of bovine pericardium used in cardiac valve bioprostheses. Implications for the mechanisms of bioprosthetic tissue mineralization. Am J Pathol 1986; 123: 134-45.
9. Ishihara T, Ferrans VJ, Boyce SW, Jones M, Roberts WC. Structure and classification of cuspal tears and perforations in porcine bioprosthetic cardiac valves implanted in patients. Am J Cardiol 1981; 48: 665-78.
10. Gendler E, Gendler S, Nimni ME. Toxic reactions evoked by glutaraldehyde-fixed pericardium and cardiac valve tissue bioprosthesis. J Biomed Mater Res 1984; 18: 727-36.
11. Chanda J, Kondoh K, Ijima K, Matsukawa M, Kuribayashi R. In vitro and in vivo calcification of vascular bioprostheses. Biomaterials 1998; 19: 1651-6.
12. Biedrzycki LM, Lerner E, Levy RJ, Schoen FJ. Differential calcification of cusps and aortic wall failed stented porcine bioprosthetic valves. J Biomed Mater Res 1997; 34: 411-5.
13. Srivatsa SS, Harrity PJ, Maercklein PB, et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest 1997; 99: 996-1009.
14. Levy RJ, Schoen FJ, Flowers WB, Staelin ST. Initiation of mineralization in bioprosthetic heart valves: studies of alkaline phosphatase activity and its inhibition by AlC13 or FeCl3 preincubations. J Biomed Mater Res 1991; 25: 905-35.Gabby
15. Gabbay S, Kadam P, Factor S, Cheung TK. Do heart valve bioprostheses degenerate for metabolic or mechanical reasons? J Thorac Cardiovasc Surg 1988; 95: 208-15.
16. Huang LL, Cheung DT, Nimni ME. Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks. J Biomed Mater Res 1990; 24: 1185-201.
17. Nimni ME, Myers D, Ertl D, Han B. Factors which affect the calcification of tissue-derived bioprostheses. J Biomed Mater Res 1997; 35: 531-7.
18. Jayakrishnan A, Jameela SR. Glutaraldehyde as a fixative in bioprostheses and drug delivery matrices. Biomaterials 1996; 17: 471-84.
19. Eybl E, Griesmacher A, Grimm M, Wolner E. Toxic effects of aldehydes released from fixed pericardium on bovine aortic endothelial cells. J Biomed Mater Res 1989; 23: 1355-65.
20. Levy RJ, Schoen FJ, Sherman FS, Nichols J, Hawley MA, Lund SA. Calcification of subcutaneously implanted type I collagen sponges. Effects of formaldehyde and glutaraldehyde pretreatments. Am J Pathol 1986; 122: 71-82.
21. Golomb G, Schoen FJ, Smith MS, Linden J, Dixon M, Levy RJ. The role of glutaraldehyde-induced cross-links in calcification of bovine pericardium used in cardiac valve bioprostheses. Am J Pathol 1987; 127: 122-30.
22. Spina M, Ortolani F, Messlemani AE, et al. Isolation of intact aortic valve scaffolds for heart-valve bioprostheses: extracellular matrix structure, prevention from calcification, and cell repopulation features. J Biomed Mater Res A 2003; 67: 1338-50.
23. Kim KM. Cells, rather than extracellular matrix, nucleate apatite in glutaraldehyde-treated vascular tissue. J Biomed Mater Res 2002; 59: 639-45.
24. Kim KM. Cellular mechanism of calcification and its prevention in glutaraldehyde treated vascular tissue. Z Kardiol 2001; 90 (suppl 3): S99-105.
25. Kim KM, Herrera GA, Battarbee HD. Role of glutaraldehyde in calcification of porcine aortic valve fibroblasts. Am J Pathol 1999; 154: 843-52.
26. Boskey AL, Boyan BD, Schwartz Z. Matrix vesicles promote mineralization in a gelatin gel. Calcif Tissue Int 1997; 60: 309-15.
27. Boskey AL. Matrix proteins and mineralization: an overview. Connect Tissue Res 1997; 35: 357-63.
28. Anderson HC. Molecular biology of matrix vesicles. Clin Orthop 1995; 31: 266-80.
29. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 1976; 35: 156-62.
30. Levy RJ, Schoen FJ, Golomb G. Bioprosthetic heart valve calcification: clinical features, pathobiology and prospects for prevention. CRC Crit Rev Biocompat 1986; 2: 147-87.
31. Tanimura A, McGregor DH, Anderson HC. Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med 1983; 172: 173-7.
32. Cunanan CM, Cabiling CM, Dinh TT, et al. Tissue characterization and calcification potential of commercial bioprosthetic heart valves. Ann Thorac Surg 2001; 7 (suppl): S417-21.
33. Chanda J, Kuribayashi R, Abe T. Role of lipid in calcification of porcine pulmonary and aortic valves. J Thorac Cardiovasc Surg 1998; 115: 259-61.
34. Jorge-Herrero E, Fernandez P, Escudero C, de-la Torre N, Zurita M, Castillo Olivares J. Influence of stress on calcification of delipidated bovine pericardial tissue employed in construction of cardiac valves. J Biomed Mater Res 1996; 30: 411-5.
35. Jorge-Herrero E, Fernandez P, de la Torre N. Inhibition of the calcification of porcine valve tissue by selective lipid removal. Biomaterials 1994; 15: 815-20.
36. Jorge-Herrero E, Fernandez P, Gutierrez M, Castillo OJ. Study of the calcification of bovine pericardium: analysis of the implication of lipids and proteoglycans. Biomaterials 1991; 12: 683-9.
37. Boskey AL. Biomineralization: Conflicts, challenges, and opportunities. J Cell Biochem 1998; 30-31 (suppl): S83-91.
38. Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19: 1852-61.
39. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001; 21: 274-301.
40. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-9.
41. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393-402.
42. Farzaneh-Far A, Proudfoot D, Shanahan C, Weissberg PL. Vascular and valvar calcification: recent advances. Heart 2001; 85: 13-7.
43. Donley GE, Fitzpatrick LA. Noncollagenous matrix proteins controlling mineralization: Possible role in pathologic calcification of vascular tissue. Trends Cardiovasc Med 1998; 8: 199-206.
44. Gura TA, Wright KL, Veis A, Webb CL. Identification of specific calcium-binding noncollagenous proteins associated with glutaraldehyde-preserved bovine pericardium in the rat subdermal model. J Biomed Mater Res 1997; 35: 483-95.
45. Shen M, Carpentier SM, Berrebi AJ, Chen L, Martinet B, Carpentier A. Protein adsorption of calcified and noncalcified valvular bioprostheses after human implantation. Ann Thorac Surg 2001; 71 (suppl): S406-7.
46. Shen M, Carpentier SM, Cambillau M, Chen L, Martinet B, Carpentier A. Protein adsorption in glutaraldehyde-preserved bovine pericardium and porcine valve tissues. Ann Thorac Surg 2001; 71 (suppl): S408-9.
47. Flanagan TC, Pandit A. Living artificial heart valve alternatives: a review. Eur Cell Mater 2003; 6: 28-45.
48. Grande-Allen KJ, Calabro A, Gupta V, Wight TN, Hascall VC, Vesely I. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading. Glycobiology 2004; 14: 621-33.
49. Grande-Allen KJ, Mako WJ, Calabro A, Shi Y, Ratliff NB, Vesely I. Loss of chondroitin 6-sulfate and hyaluronan from failed porcine bioprosthetic valves. J Biomed Mater Res 2003; 65: 251-9.
50. Vyavahare N, Ogle M, Schoen FJ, et al. Mechanisms of bioprosthetic heart valve failure: Fatigue causes collagen denaturation and glycosaminoglycan loss. J Biomed Mater Res 1999; 46: 44-50.
51. Simionescu D, Iozzo RV, Kefalides NA. Bovine pericardial proteoglycan: biochemical, immunochemical and ultrastructural studies. Matrix 1989; 9: 301-10.
52. Chen CC, Boskey AL. The effects of proteoglycans from different cartilage types on in vitro hydroxyapatite proliferation. Calcif Tissue Int 1986; 39: 324-7.
53. Hunter GK, Allen BL, Grynpas MD, Cheng PT. Inhibition of hydroxyapatite formation in collagen gels by chondroitin sulphate. Biochem J 1985; 228: 463-9.
54. Anselme K, Petite H, Herbage D. Inhibition of calcification in vivo by acyl azide cross-linking of a collagen-glycosaminoglycan sponge. Matrix 1992; 12: 264-73.
55. Hanthamrongwit M, Reid WH, Grant MH. Chondroitin-6-sulphate incorporated into collagen gels for the growth of human keratinocytes: the effect of cross-linking agents and diamines. Biomaterials 1996; 17: 775-80.
56. Pieper JS, Oosterhof A, Dijkstra PJ, Veerkamp JH, van Kuppevelt TH. Preparation and characterization of porous crosslinked collagenous matrices containing bioavailable chondroitin sulphate. Biomaterials 1999; 20: 847-58.
57. Lovekamp J, Vyavahare N. Periodate-mediated glycosaminoglycan stabilization in bioprosthetic heart valves. J Biomed Mater Res 2001; 56: 478-86.
58. Arenaz B, Maestro MM, Fernandez P, et al. Effects of periodate and chondroitin 4-sulfate on proteoglycan stabilization of ostrich pericardium. Inhibition of calcification in subcutaneous implants in rats. Biomaterials 2004; 25: 3359-68.
59. Beck GR, Jr., Zerler B, Moran E. Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci USA 2000; 97: 8352-7.
60. Taira T, Iijima M, Moriwaki Y, Kuboki Y. A new method for in vitro calcification using acrylamide gel and bovine serum. Connect Tissue Res 1995; 33: 185-92.
61. van den BT, Oosting J, Everts V, Beertsen W. Mineralization of alkaline phosphatase-complexed collagen implants in the rat in relation to serum inorganic phosphate. J Bone Miner Res 1995; 10: 616-24.
62. Vasudev SC, Chandy T, Sharma CP, Mohanty M, Umasankar PR. Synergistic effect of released aspirin/heparin for preventing bovine pericardial calcification. Artif Organs 2000; 24: 129-36.
63. Bode W, Maskos K. Structural studies on MMPs and TIMPs. Methods Mol Biol 2001; 151: 45-77.
64. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999; 55: 639-52.
65. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075-95.
66. Kahari VM, Saarialho KU. Matrix metalloproteinases in skin. Exp Dermatol 1997; 6: 199-213.
67. Simionescu DT, Lovekamp JJ, Vyavahare NR. Extra-cellular matrix degrading enzymes are active in porcine stentless aortic bioprosthetic heart valves. J Biomed Mater Res A 2003; 66: 755-63.
68. Simionescu A, Simionescu D, Deac RF. Matrix metalloproteinases in the pathology of natural and bioprosthetic cardiac valves. Cardiovasc Pathol 1996; 5: 323-32.
69. Calero P, Jorge-Herrero E, Turnay J, et al. Gelatinases in soft tissue biomaterials. Analysis of different crosslinking agents. Biomaterials 2002; 23: 3473-8.
70. Petite H, Duval JL, Frei V, Abdul-Malak N, Sigot-Luizard MF, Herbage D. Cytocompatibility of calf pericardium treated by glutaraldehyde and by the acyl azide methods in an organotypic culture model. Biomaterials 1995; 16: 1003-8.
71. Petite H, Frei V, Hue A, Herbage D. Use of diphenylphosphorylazide for cross-linking collagen-based biomaterials. J Biomed Mater Res 1994; 28: 159-65.
72. Ishihara T, Ferrans VJ, Jones M, Cabin HS, Roberts WC. Calcific deposits developing in a bovine pericardial bioprosthetic valve 3 days after implantation. Circulation 1981; 63: 718-23.
73. Ferrans VJ, Boyce SW, Billingham ME, Jones M, Ishihara T, Roberts WC. Calcific deposits in porcine bioprostheses: structure and pathogenesis. Am J Cardiol 1980; 46: 721-34.
74. Vesely I. The evolution of bioprosthetic heart valve design and its impact on durability. Cardiovasc Pathol 2003; 12: 277-86.
75. Mako WJ, Vesely I. In vivo and in vitro models of calcification in porcine aortic valve cusps. J Heart Valve Dis 1997; 6: 316-23.
76. Vesely I, Barber JE, Ratliff NB. Tissue damage and calcification may be independent mechanisms of bioprosthetic heart valve failure. J Heart Valve Dis 2001; 10: 471-7.
77. Deiwick M, Glasmacher B, Pettenazzo E, et al. Primary tissue failure of bioprostheses: new evidence from in vitro tests. Thorac Cardiovasc Surg 2001; 49: 78-83.
78. Pettenazzo E, Deiwick M, Thiene G, et al. Dynamic in vitro calcification of bioprosthetic porcine valves: evidence of apatite crystallization. J Thorac Cardiovasc Surg 2001; 121: 500-9.
79. Deiwick M, Glasmacher B, Baba HA, et al. In vitro testing of bioprostheses: influence of mechanical stresses and lipids on calcification. Ann Thorac Surg 1998; 66 (suppl): S206-11.
80. Ellsmere JC, Khanna RA, Lee JM. Mechanical loading of bovine pericardium accelerates enzymatic degradation. Biomaterials 1999; 20: 1143-50.
81. Khor E. Methods for the treatment of collagenous tissues for bioprostheses. Biomaterials 1997; 18: 95-105.
82. Nimni ME, Cheung D, Strates B, Kodama M, Sheikh K. Chemically modified collagen: a natural biomaterial for tissue replacement. J Biomed Mater Res 1987; 21: 741-71.
83. Gratzer PF, Lee JM. Altered mechanical properties in aortic elastic tissue using glutaraldehyde/solvent solutions of various dielectric constant. J Biomed Mater Res 1997; 37: 497-507.
84. Gratzer PF, Pereira CA, Lee JM. Solvent environment modulates effects of glutaraldehyde crosslinking on tissue-derived biomaterials. J Biomed Mater Res 1996; 31: 533-43.
85. Cheung DT, Tong D, Perelman N, Ertl D, Nimni ME. Mechanism of crosslinking of proteins by glutaraldehyde. IV: In vitro and in vivo stability of a crosslinked collagen matrix. Connect Tissue Res 1990; 25: 27-34.
86. Cheung DT, Perelman N, Ko EC, Nimni ME. Mechanism of crosslinking of proteins by glutaraldehyde III. Reaction with collagen in tissues. Connect Tissue Res 1985; 13: 109-15.
87. Olde DL, Dijkstra PJ, van LM, van WP, Nieuwenhuis P, Feijen J. In vitro degradation of dermal sheep collagen cross-linked using a water-soluble carbodiimide. Biomaterials 1996; 17: 679-84.
88. Olde Damink LH, Dijkstra PJ, et al. Cross-linking of dermal sheep collagen using a water-soluble carbodiimide. Biomaterials 1996; 17: 765-73.
89. Olde Damink LH, Dijkstra PJ, van Luyn MJ, van Wachem PB, Nieuwenhuis P, Feijen J. In vitro degradation of dermal sheep collagen cross-linked using a water-soluble carbodiimide. Biomaterials 1996; 17: 679-84.
90. Jorge-Herrero E, Fernandez P, Turnay J, et al. Influence of different chemical cross-linking treatments on the properties of bovine pericardium and collagen. Biomaterials 1999; 20: 539-45.
91. Tu R, Shen SH, Lin D, et al. Fixation of bioprosthetic tissues with monofunctional and multifunctional polyepoxy compounds. J Biomed Mater Res 1994; 28: 677-84.
92. Shen SH, Sung HW, Tu R, et al. Characterization of a polyepoxy compound fixed porcine heart valve bioprosthesis. J Appl Biomater 1994; 5: 159-62.
93. Weil L, Gordon W, Buchert A. Photooxidation of amino acids in the presence of methylene blue. Arch Biochem Biophys 1951; 33: 90-109.
94. Meuris B, Phillips R, Moore MA, Flameng W. Porcine stentless bioprostheses: prevention of aortic wall calcification by dye-mediated photo-oxidation. Artif Organs 2003; 27: 537-43.
95. Thubrikar MJ, Nolan SP, Deck JD, Aouad J, Levitt LC. Intrinsic calcification of T6-processed and control porcine and bovine bioprostheses in calves. Trans Am Soc Artif Intern Organs 1983; 29: 245-9.
96. Flameng WJ, Ozaki S, Yperman J, et al. Calcification characteristics of porcine stented valves in a juvenile sheep model. Ann Thorac Surg 2001; 7 (suppl): S401-5.
97. Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Circulation 1997; 95: 479-88.
98. Gott JP, Girardot MN, Girardot JM, et al. Refinement of the alpha aminooleic acid bioprosthetic valve anticalcification technique. Ann Thorac Surg 1997; 64: 50-8.
99. Gott JP, Pan C, Dorsey LM, et al. Calcification of porcine valves: a successful new method of antimineralization. Ann Thorac Surg 1992; 53: 207-15.
100. Chen W, Kim JD, Schoen FJ, Levy RJ. Effect of 2-amino oleic acid exposure conditions on the inhibition of calcification of glutaraldehyde cross-linked porcine aortic valves. J Biomed Mater Res 1994; 28: 1485-95.
101. 3+ binding studies and metallic cation effects on bioprosthetic heart valve calcification in the rat subdermal model [see comments]. ASAIO Trans 1990; 36: 56-9.
102. 3+ and aminodiphosphonate preincubations. Am J Pathol 1992; 141: 487-96.
103. 3+ for prevention of bioprosthetic heart valve calcification. ASAIO Trans 1990; 36: M408-10.
104. 3 in rat subdermal model studies. Am J Pathol 1991; 138: 971-81.
105. Levy RJ, Schoen FJ, Lund SA, Smith MS. Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. Experimental studies of optimal dosages and therapeutic durations. J Thorac Cardiovasc Surg 1987; 94: 551-7.
106. Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ. Inhibition of bioprosthetic heart valve calcification by sustained local delivery of Ca and Na diphosphonate via controlled release matrices. ASAIO Trans 1986; 32: 587-90.
107. Levy RJ, Golomb G, Wolfrum J, Lund SA, Schoen FJ, Langer R. Local controlled-release of diphosphonates from ethylenevinylacetate matrices prevents bioprosthetic heart valve calcification. Trans Am Soc Artif Intern Organs 1985; 31: 459-63.
108. lOS.Alferiev I, Vyavahare N, Song C, et al. Bisphosphonate derivatized polyurethanes resist calcification. Biomaterials 2001; 22: 2683-93.
109. Levy RJ, Hawley MA, Schoen FJ, Lund SA, Liu PY. Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats. Circulation 1985; 71: 349-56.
110. Webb CL, Benedict JJ, Schoen FJ, Linden JA, Levy RJ. Inhibition of bioprosthetic heart valve calcification with covalently bound aminopropanehydroxydiphosphonate. ASAIO Trans 1987; 33: 592-5.
111. Chang Y, Tsai CC, Liang HC, Sung HW. In vivo evaluation of cellular and acellular bovine pericardia fixed with a naturally occurring crosslinking agent (genipin). Biomaterials 2002; 23: 2447-57.
112. Chang Y, Lee MH, Liang HC, Hsu CK, Sung HW. Acellular bovine pericardia with distinct porous structures fixed with genipin as an extracellular matrix. Tissue Eng 2004; 10: 881-92.
113. HS.Naimark WA, Pereira CA, Tsang K, Lee JM. HMDC crosslinking of bovine pericardial tissue: a potential role of the solvent environment in the design of bioprosthetic materials. J Mater Sci Mater Med 1995; 6: 235-41.
114. Khouw IM, van Wachem PB, Molema G, Plantinga JA, de Leij LF, van Luyn MJ. The foreign body reaction to a biodegradable biomaterial differs between rats and mice. J Biomed Mater Res 2000; 52: 439-46.
115. Goissis G, Yoshioka SA, Braile DM, Ramirez VD. The chemical protecting group concept applied in crosslinking of natural tissues with glutaraldehyde acetals. Artif Organs 1998; 22: 210-4.
116. Vasudev SC, Chandy T. Polyethylene glycol-grafted bovine pericardium: a novel hybrid tissue resistant to calcification. J Mater Sci Mater Med 1999; 10: 121-8.
117. Vasudev SC, Chandy T, Sharma CP, Mohanty M, Umasankar PR. Effects of double cross-linking technique on the enzymatic degradation and calcification of bovine pericardia. J Biomater Appl 2000; 14: 273-95.
118. HS. Jorge-Herrero E, Fernandez P, Escudero C, Garcia-Paez JM, Castillo-Olivares JL. Calcification of pericardial tissue pretreated with different amino acids. Biomaterials 1996; 17: 571-5.
119. Zilla P, Fullard L, Trescony P, et al. Glutaraldehyde detoxification of aortic wall tissue: a promising perspective for emerging bioprosthetic valve concepts. J Heart Valve Dis 1997; 6: 510-20.
120. Jorge-Herrero E, Fernandez P, Gutierrez M, Castillo-Olivares JL. Study of the calcification of bovine pericardium: analysis of the implication of lipids and proteoglycans. Biomaterials 1991; 12: 683-9.
121. 3 and ethanehydroxydiphosphonate: preincubation and polymeric controlled release studies. Biomaterials 1993; 14: 705-11.
122. Santin M, Motta A, Cannas M. Changes in serum conditioning profiles of glutaraldehyde-crosslinked collagen sponges after their treatment with calcification inhibitors. J Biomed Mater Res 1998; 40: 434-41.
123. Ogle MF, Kelly SJ, Bianco RW, Levy RJ. Calcification resistance with aluminum-ethanol treated porcine aortic valve bioprostheses in juvenile sheep. Ann Thorac Surg 2003; 75: 1267-73.
124. Bailey MT, Pillarisetti S, Xiao H, Vyavahare NR. Role of elastin in pathologic calcification of xenograft heart valves. J Biomed Mater Res A 2003; 66: 93-102.
125. Chanda J, Kuribayashi R, Abe T. Heparin coupling in inhibition of calcification of vascular bioprostheses. Biomaterials 1999; 20: 1753-7.
126. Huma P, Bezuidenhout D, Torrianni M, Hendriks M, Zilla P. Optimization of diamine bridges in glutaraldehyde treated bioprosthetic aortic wall tissue. Biomaterials 2002; 23: 2099-103.
127. Zilla P, Weissenstein C, Bracher M, et al. High glutaraldehyde concentrations reduce rather than increase the calcification of aortic wall tissue. J Heart Valve Dis 1997; 6: 502-9.
128. Isenburg JC, Simionescu DT, Vyavahare NR. Tannic acid treatment enhances biostability and reduces calcification of glutaraldehyde fixed aortic wall. Biomaterials 2005; 26: 1237-45.
129. Isenburg JC, Simionescu DT, Vyavahare NR. Elastin stabilization in cardiovascular implants: improved resistance to enzymatic degradation by treatment with tannic acid. Biomaterials 2004; 25: 3293-302.
130. Huang LL, Sung HW, Tsai CC, Huang DM. Biocompatibility study of a biological tissue fixed with a naturally occurring crosslinking reagent. J Biomed Mater Res 1998; 42: 568-76.